Navigation Links
Therabron Therapeutics Receives Accelerated Second Tranche from Series B Financing and Expands Investor Syndicate

ROCKVILLE, Md., Nov. 9, 2015 /PRNewswire/ -- Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that the Company has received an accelerated second tranche from its previously announced Series B financing and expanded its investor syndicate with gross proceeds of up to $6.75 million. Brace Pharma Capital led the financing.

"The last year has been important for Therabron as we are now moving toward the end of patient enrollment in the phase 2 clinical trial for CG100 and have advanced our scientific understanding of the broad potential of our recombinant human secretoglobin platform across several respiratory disorders," said Dr. Thomas F. Miller, President of Therabron. "We are thrilled that our investors have continued confidence in Therabron and endorse our strategy to expand the scope of development of our proprietary platform."

The Company's lead product candidate, CG100, is currently being investigated in a phase 2 clinical trial for the prevention of chronic respiratory morbidities (CRM) in preterm infants. Therabron anticipates enrollment for this study to be completed by the end of 2015.

Therabron is also advancing other promising programs with the goal of opening a second IND in 2016 targeting patients in the Pediatric Intensive Care Unit (PICU) where pathogen infections, such as influenza and respiratory syncytial virus (RSV) can lead to respiratory failure.  Additional lead optimization activities will also progress for newly created analogues of recombinant human CC10 proteins intended to target ambulatory respiratory disorders, such as chronic obstructive pulmonary disease (COPD).

About Therabron Therapeutics, Inc.

Therabron Therapeutics, Inc. is a clinical-stage biotechnology company, founded in 2007 and located in Rockville, MD.  Therabron is focused on the advancement of respiratory therapeutics with disease-modifying potential. The Company's product candidates aim to restore the natural immune balance in the lungs of patients with respiratory disorders through the administration of recombinant human CC10 proteins. The family of CC10 proteins, also known as secretoglobins, has the potential to change the course of acute and chronic respiratory diseases, representing large markets into which few truly novel drugs have been introduced. Therabron's product candidates have the potential to be first-in-class, disease-modifying, breakthrough biologic therapeutics. For additional information, please visit


SOURCE Therabron Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program
2. Clinical Data Featuring Trovagenes Precision Cancer Monitoring Platform to be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
4. Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022 - Reportlinker Review
5. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015
6. Relmada Therapeutics Responds to 13D Filing by Laidlaw
7. Envisia Therapeutics Selected To Present During Drug Delivery Company Showcase At 2015 Ophthalmalogy Innovation Summit
8. Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy
9. Viking Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update
10. Global Antiviral Therapeutics Technologies, Markets and Companies Analysis Report 2015-2024
11. Johnson & Johnson Announces Agreement To Acquire Novira Therapeutics, Inc.
Post Your Comments:
(Date:2/20/2020)... , ... February 20, 2020 , ... Enquire, a leading ... and post-acute care, is proud to announce G5 as a Silver Sponsor of Enquire ... “G5 is proud to return to Enquire Summit as a Silver Sponsor. This event ...
(Date:2/19/2020)... ... , ... A new study released today in STEM CELLS Translational Medicine is ... a compressed spinal cord. It is also the first to show how transplanting basic ... enhances the injured spinal cord’s recovery. , The study, conducted on a rat ...
(Date:2/19/2020)... ... 19, 2020 , ... Cancer diagnostics is a highly dynamic ... becoming popular as they enable accurate diagnosis as well as prognosis evaluation, which ... including histology and assays, reached $1.6 billion, increasing 11.5% over roughly $1.435 billion ...
Breaking Medicine Technology:
(Date:2/19/2020)... ... February 19, 2020 , ... Spaulding Youth ... $10,000.00 from the Doug Flutie, Jr. Foundation for Autism. The grant will directly ... , The physical fitness program will include the hiring of a fitness professional ...
(Date:2/19/2020)... ... February 19, 2020 , ... The American College of ... new Lifestyle Medicine Residency Curriculum (LMRC). The curriculum is the first comprehensive, applicable ... Driven by resident involvement, the curriculum has included residents in every aspect ...
(Date:2/19/2020)... ... February 19, 2020 , ... MedTech IGNITE Expands ... Apply to Participate in 2020 Cohort , The Massachusetts Medical Device Industry Council ... now accepting applications from startup founders and CEOs to participate in the 2020 ...
(Date:2/19/2020)... ... February 19, 2020 , ... BPM+ Health ... announced that it will participate in the HIMSS20 Global Health Conference ... engage healthcare professionals and other stakeholders at HIMSS20 – the largest global health ...
(Date:2/19/2020)... ... February 19, 2020 , ... SEAL SHIELD, LLC - Almost a hundred thousand ... (HAIs.) According to The Centers for Disease Control (CDC), 80% of infections are transmitted ... that are now acting as an extension of people’s hands, but not getting cleaned ...
Breaking Medicine News(10 mins):